Evolent Health (NYSE:EVH) Stock Price Up 4.8% – Should You Buy?

Posted by George Bondi on Oct 15th, 2026

Evolent Health, Inc (NYSE:EVH – Get Free Report) shares were up 4.8% during trading on Tuesday. The stock traded as high as $4.46 and last traded at $4.4550. Approximately 563,018 shares changed hands during trading, a decline of 81% from the average session volume of 2,918,336 shares. The stock had previously closed at $4.25.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EVH. JPMorgan Chase & Co. boosted their price target on Evolent Health from $5.00 to $6.00 and gave the company an “overweight” rating in a research note on Tuesday, August 18th. Citigroup raised Evolent Health from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $6.75 to $6.00 in a research report on Monday, August 10th. Weiss Ratings upgraded Evolent Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Truist Financial dropped their price objective on Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Finally, TD Cowen lifted their price objective on Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a report on Monday, August 17th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Evolent Health has a consensus rating of “Moderate Buy” and a consensus target price of $5.96.

View Our Latest Report on Evolent Health

Evolent Health Price Performance

The firm has a market cap of $535.23 million, a P/E ratio of -1.04 and a beta of 1.02. The company has a debt-to-equity ratio of 2.52, a current ratio of 1.24 and a quick ratio of 1.24. The company’s 50-day moving average is $4.12 and its two-hundred day moving average is $4.09.

Evolent Health (NYSE:EVH – Get Free Report) last issued its earnings results on Thursday, August 6th. The technology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The company had revenue of $484.50 million during the quarter, compared to analysts’ expectations of $597.70 million. During the same period in the previous year, the company earned ($0.10) EPS. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year. Sell-side analysts anticipate that Evolent Health, Inc will post -0.25 EPS for the current fiscal year.

Insider Transactions at Evolent Health

In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total transaction of $329,460.00. Following the completion of the transaction, the president directly owned 655,133 shares in the company, valued at $3,275,665. The trade was a 9.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Evolent Health

Large investors have recently modified their holdings of the business. Maverick Capital Ltd. grew its position in Evolent Health by 1.3% in the first quarter. Maverick Capital Ltd. now owns 2,572,763 shares of the technology company’s stock valued at $5,866,000 after acquiring an additional 32,833 shares during the last quarter. Castle Hook Partners LP acquired a new position in Evolent Health during the fourth quarter worth about $3,751,000. Sei Investments Co. lifted its holdings in shares of Evolent Health by 50.8% in the first quarter. Sei Investments Co. now owns 302,281 shares of the technology company’s stock worth $689,000 after acquiring an additional 101,867 shares during the last quarter. Congress Asset Management Co. increased its holdings in shares of Evolent Health by 20.3% during the third quarter. Congress Asset Management Co. now owns 275,158 shares of the technology company’s stock worth $960,000 after buying an additional 46,466 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in Evolent Health in the first quarter valued at about $488,000.

About Evolent Health

(Get Free Report)

Evolent Health, Inc is a healthcare services and technology company that helps health plans and providers manage specialty care and transition to value-based models. Its offerings are designed to coordinate care, improve clinical outcomes and support more predictable healthcare costs across complex medical conditions.

The company provides technology-enabled administrative, clinical and analytical services for areas such as oncology, cardiology, musculoskeletal care and other specialty-care categories.